Projects per year
Personal profile
Education
- MD, College of Medicine, National Defense Medical Center, Taipei, Taiwan.
Experience
- 2022.11- Superintendent, Taipei Cancer Center, Taipei Medical University
- 2022.11- Director, Research Center of Cancer Translational Medicine, Taipei Medical University
- 2022.04- 泰福生技股份有限公司 獨立董事
- 2020.11- Distinguished Investigator and Director of Institute of Biotechnology and Pharmaceutical Research, NHRI
- 2020.08 Distinguished Investigator and Attending Physician of National Institute of Cancer Research, NHRI
- 2020.08 Professor Emeritus, National Cheng Kung University
- 2019.02-2020.07 Executive Vice President, National Cheng Kung University
- 2019.02-2020.07 Director of University Center for Bioscience and biotechnology, NCKU
- 2019.01-2020.12 教育部醫學教育會 委員
- 2015.01-2016.12 教育部醫學教育會 委員
- 2014.08-2019.07 Distinguished Professor and Dean, College of Medicine, National Cheng Kung University
- 2013.08-2014.07 Professor and Dean, College of Medicine, National Cheng Kung University
- 2008.09-2018.05 Distinguished Investigator of National Institute of Cancer Research, NHRI
- 2008.01-2013.07 Director of National Institute of Cancer Research, NHRI
- 2007.08~ Attending Physician of Division of hematology/Oncology, NCKUH
- 2007.08-2013.07 Joined Professor, College of Medicine, National Cheng Kung University
- 2006.01-2007.12 Deputy Director of National Institute of Cancer Research, NHRI
- 2004.06-2008 Chairman of Safety and Data Monitoring committee, TCOG
- 2004.04-2008.08 Investigator of NHRI
- 2003.08-2007.07 Adjunct Professor of Internal Medicine, NDMC (部定,教字013198)
- 2003-2005 常務理事,Chinese Oncology Society
- 2001~ Board member of Chinese Oncology Society
- 2000.09-2004.03 Associate investigator of NHRI
- 1999 ~ Board member of Sino-American Cancer Foundation
- 1997-2006 Adjunct Attending physician of Department of Oncology, NTUH
- 1997~ Senior Attending physician of NHRI
- 1997-2001 General Secretary of Chinese Oncology Society
- 1997 Chief of Hematology / Oncology, Cheng-Hsien Medical
Center - 1994-2003.07 Associate Professor of internal medicine, NDMC (部定,副字 21234)
- 1994-1996 Board member of Chinese BMT Society
- 1993-1996 Chief of Medical Oncology, Tri-Service General Hospital, National Defense Medical Center
- 1991-1992 Attending physician of Medical Mission in Republic of Central Africa
- 1989-1991 Visiting Scholar of Yale Medical School, Department of Pharmacology
- 1987-1989 Fellow of Medical Oncology Training Program of Institute of Biomedical Science, Academia Sinica
- 1987-1996 Attending Physician of Hematology / Oncology, Tri-Service General Hospital, NDMC
- 1986-1987 Chief resident of Division of Hematology / Oncology,
Department of Internal Medicine, TSGH, NDMC - 1982-1986 Resident of Department of Medicine, TSGH, NDMC
- 1981-1982 Internship training, Tri-Service General Hospital
Research Interests
- Development of anticancer drugs
- Study the mechanisms of anticancer drug resistance
Fingerprint
- 1 Similar Profiles
Network
Projects
- 2 Active
-
探討cathepsin S在奧沙利鉑引起的神經病變的作用角色: 預測和預防周邊神經病變的潛在生物標誌(3/3)
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
腫瘤微環境中癌細胞與免疫因子的串擾:頭頸癌的組織蛋白酶S相關調節機制鑑定和治療策略-溶酶體半胱氨酸蛋白酶組織蛋白酶S在頭頸癌腫瘤免疫中的作用:聚焦對IL-7的調節角色和潛在的免疫調節機制(2/3)
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy
Chen, Y. F., Wu, C. H., Chen, L. H., Lee, H. W., Lee, J. C., Yeh, T. K., Chang, J. Y., Chou, M. C., Wu, H. L., Lai, Y. P., Song, J. S., Yeh, K. C., Chen, C. T., Lee, C. J., Shia, K. S. & Shen, M. R., Mar 24 2022, In: Journal of Medicinal Chemistry. 65, 6, p. 4767-4782 16 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells
Tangeda, V., Lo, Y. K., Babuharisankar, A. P., Chou, H. Y., Kuo, C. L., Kao, Y. H., Lee, A. Y. L. & Chang, J. Y., Mar 2022, In: Cell Death and Disease. 13, 3, 241.Research output: Contribution to journal › Article › peer-review
Open Access5 Citations (Scopus) -
The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b
Lee, Y. Z., Hsu, H. Y., Yang, C. W., Lin, Y. L., Chang, S. Y., Yang, R. B., Liang, J. J., Chao, T. L., Liao, C. C., Kao, H. C., Chang, J. Y., Sytwu, H. K., Chen, C. T. & Lee, S. J., Jul 2022, In: Pharmaceutics. 14, 7, 1511.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells
Tang, Y. C., Chang, H. H., Chen, H. H., Yao, J. Y., Chen, Y. T., Chuang, Y. J., Chang, J. Y. & Kuo, C. C., 2021, In: Journal of Food and Drug Analysis. 29, 4, 7.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation
Tang, Y. C., Hsiao, J. R., Jiang, S. S., Chang, J. Y., Chu, P. Y., Liu, K. J., Fang, H. L., Lin, L. M., Chen, H. H., Huang, Y. W., Chen, Y. T., Tsai, F. Y., Lin, S. F., Chuang, Y. J. & Kuo, C. C., Mar 11 2021, In: Theranostics. 11, 11, p. 5232-5247 16 p.Research output: Contribution to journal › Article › peer-review
Open Access34 Citations (Scopus)
Datasets
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I. (Contributor), Kuo, C. (Contributor), Liou, J. (Creator) & Chang, J. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
Dataset